Normal saline 0.9% infusion solution (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 22 | Moyamoya disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04205578 (ClinicalTrials.gov) | January 2020 | 18/12/2019 | NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events | A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery | Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack | Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution | yuanli Zhao | Peking University International Hospital | Not yet recruiting | 18 Years | 60 Years | All | 450 | Phase 3 | China |